Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effects of Listing and Delisting in National Essential Medicine List on Utilization Patterns Sauwakon Ratanawijitrasin, PhD and Sanita Hirunrassamee, PhD.

Published byGeoffrey Fordham Modified over 10 years ago

Similar presentations

Presentation on theme: "Effects of Listing and Delisting in National Essential Medicine List on Utilization Patterns Sauwakon Ratanawijitrasin, PhD and Sanita Hirunrassamee, PhD."— Presentation transcript:

1 Effects of Listing and Delisting in National Essential Medicine List on Utilization Patterns Sauwakon Ratanawijitrasin, PhD and Sanita Hirunrassamee, PhD

2 Background pharmacological categoryGeneric NEML 20042008 Lipid-regulating drugs Lipid-regulating drugs Simvastatin Atorvastatin Rosuvastatin Dugs affecting the renin-angiotensin system Enalapril maleate Losartan potassium Valsartan Drugs used in the control of epilepsy Sodium valproate Topiramate Levitriacetam Gabapentin Pregabapentin

3 Objective To examine the effects of NEML listing and delisting on the utilization patterns comparing: Delisted drugs with remaining or Added medicines non-essential medicines (NEM- not listed in both NEML editions) in the same pharmacological category NEML: National Essential Medicine List

4 Methodology 9 government hospitals 1.Statins 2.ACEIs 3.Anti- epileptics Segmented Regression Analysis of interrupted time series data OPD e-dispensing databases Statistics 3 groups of Medicine Data Source: Dispensing data collected for "Data management for systematic monitoring of drug utilization and policy project"--a collaboration between IMRTA and PharReD Foundation.

5 Methodology (cont.) Before NEML After 14 mo2008 10 mo 24 months time-series data points

6 Methodology (cont.) Statins - 130,287 pt ACEIs & AIIAs - 85,349 pt Anti-epileptics 31,739 pt Comparison 3 major health insurance schemes CSMBS SSS UC

7 RESULTS

8

9 Utilization Patterns across Health Insurance Scheme

10 Conclusion NS No statistical significant changes in the utilization patterns of the listed, delisted and non-listed medicines occurred after the introduction of the 2008 NEML Sig. Discrepancies in utilization were found among patients in different health insurance systems. Ans. It appears that health insurance policy exerts greater influence on utilization patterns than essential medicine policy.

11 Acknowledgement: Institute of Medical Research Technology Assessment (IMRTA) and Pharmaceutical System Research & Development Foundation (PharReD Foundation)

Download ppt "Effects of Listing and Delisting in National Essential Medicine List on Utilization Patterns Sauwakon Ratanawijitrasin, PhD and Sanita Hirunrassamee, PhD."

Similar presentations

Medicines Prices and Methods of Financing in South-East Asia Indian Pharmacological Society 38 th Annual Conference, Chennai 29th December 2005 Dr K Weerasuriya,

Medicines Prices and Methods of Financing in South-East Asia Indian Pharmacological Society 38 th Annual Conference, Chennai 29th December 2005 Dr K Weerasuriya,
Effects of Telehealth on the Self Management of Heart Failure Brendon Colaco, M.B.B.S., M.H.A Kathryn H. Dansky, PhD, RN Kathryn H. Bowles, PhD, RN.

Effects of Telehealth on the Self Management of Heart Failure Brendon Colaco, M.B.B.S., M.H.A Kathryn H. Dansky, PhD, RN Kathryn H. Bowles, PhD, RN.
1 Exploration of Health Care Providers Behavior to Keep Their Revenues after Reduction of Payment Generosity --- A Case of Drug Payment in Taiwan Likwang.

1 Exploration of Health Care Providers Behavior to Keep Their Revenues after Reduction of Payment Generosity --- A Case of Drug Payment in Taiwan Likwang.
ASSESSMENT OF PUBLIC HEALTH AND HEALTHCARE PREPAREDNESS CAPABILITIES: ANALYZING CORRECTIVE ACTIONS TO IDENTIFY PRIORITIES Lisa McCormick, DrPH; Jonathan.

ASSESSMENT OF PUBLIC HEALTH AND HEALTHCARE PREPAREDNESS CAPABILITIES: ANALYZING CORRECTIVE ACTIONS TO IDENTIFY PRIORITIES Lisa McCormick, DrPH; Jonathan.
Longitudinal Analysis of Market Utilization / Pharmaceutical Sales Data Christine Lu Harvard Medical School and Harvard Pilgrim Health Care Institute WHO.

Longitudinal Analysis of Market Utilization / Pharmaceutical Sales Data Christine Lu Harvard Medical School and Harvard Pilgrim Health Care Institute WHO.
Changes in Use of Antidiabetic Medications Following Price Regulations in China (1999-2009) Christine Lu Harvard Medical School and Harvard Pilgrim Health.

Changes in Use of Antidiabetic Medications Following Price Regulations in China ( ) Christine Lu Harvard Medical School and Harvard Pilgrim Health.
Fig.3 Adverse effects of antiepileptic therapy in children: poly-therapy vs mono-therapy In-Service, Problem-Based Pharmacotherapy Teaching and Clinical.

Fig.3 Adverse effects of antiepileptic therapy in children: poly-therapy vs mono-therapy In-Service, Problem-Based Pharmacotherapy Teaching and Clinical.
Predictors of Emergency Department Utilization by Homeless Persons: A National Study Clarilee Hauser PhD, RN.

Predictors of Emergency Department Utilization by Homeless Persons: A National Study Clarilee Hauser PhD, RN.
Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States Ian H. de Boer, MD, MS, Tessa C. Rue, MS, Yoshio N. Hall, MD, Patrick.

Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States Ian H. de Boer, MD, MS, Tessa C. Rue, MS, Yoshio N. Hall, MD, Patrick.
Assessing the impact of a policy on universal coverage on financial risk protection, health care finance, and benefit incidence of the Thai health care.

Assessing the impact of a policy on universal coverage on financial risk protection, health care finance, and benefit incidence of the Thai health care.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.

1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Rankings: What do they matter, what do they measure? Anne McFarlane August 18, 2010.

Rankings: What do they matter, what do they measure? Anne McFarlane August 18, 2010.
Planning, Public Policy & Management The University of Oregon Consumer Driven Health Care Summit September 14, 2006 Funded by Changes in Health Care Financing.

Planning, Public Policy & Management The University of Oregon Consumer Driven Health Care Summit September 14, 2006 Funded by Changes in Health Care Financing.
Planning, Public Policy & Management The University of Oregon Jessica Greene, PhD Judith Hibbard, DrPH James F. Murray, PhD Steven M. Teutsch MD, MPH Marc.

Planning, Public Policy & Management The University of Oregon Jessica Greene, PhD Judith Hibbard, DrPH James F. Murray, PhD Steven M. Teutsch MD, MPH Marc.
Active Pharmaceutical Management Strategies of Health Insurance Systems to Improve Cost-Effective Use of Medicines in Low- and Middle-Income Countries:

Active Pharmaceutical Management Strategies of Health Insurance Systems to Improve Cost-Effective Use of Medicines in Low- and Middle-Income Countries:
Sakthivel Selvaraj, Habib Hasan Public Health Foundation of India, India 1.

Sakthivel Selvaraj, Habib Hasan Public Health Foundation of India, India 1.
TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.

TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.
The Effect of Quality Improvement on Racial Disparities in Diabetes Care Thomas D. Sequist, MD MPH Alyce S. Adams, PhD Fang Zhang, MS Dennis Ross-Degnan,

The Effect of Quality Improvement on Racial Disparities in Diabetes Care Thomas D. Sequist, MD MPH Alyce S. Adams, PhD Fang Zhang, MS Dennis Ross-Degnan,
1 DRUG DATABASE AND PERFORMANCE INDICATORS FOR UTILIZATION MONITORING Authors: Pongcharoensuk P 1, Angsanant M 2, Chantrakunopars P 2, Phuthong P 1, Kongsawat.

1 DRUG DATABASE AND PERFORMANCE INDICATORS FOR UTILIZATION MONITORING Authors: Pongcharoensuk P 1, Angsanant M 2, Chantrakunopars P 2, Phuthong P 1, Kongsawat.
The Economic Impact of Pharmaceutical Parallel Trade: A Stakeholder Analysis Panos Kanavos, PhD London School of Economics, UK AcademyHealth, San Diego,

The Economic Impact of Pharmaceutical Parallel Trade: A Stakeholder Analysis Panos Kanavos, PhD London School of Economics, UK AcademyHealth, San Diego,

Similar presentations

Ads by Google